Interstitial Lung Disease Autoantibody Panel
Ordering Recommendation

May be useful for evaluation of interstitial lung disease in the context of connective tissue disease.

Qualitative Immunoprecipitation/Semi-Quantitative Multiplex Bead Assay/Qualitative Immunoblot/Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Quantitative Immunoturbidimetry
7-18 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Serum Separator Tube (SST). 
Specimen Preparation
Separate from cells ASAP or within 2 hours of collection. Transfer five 1 mL serum aliquots to ARUP Standard Transport Tubes. (Min: 0.5 mL/aliquot) 
Storage/Transport Temperature
Unacceptable Conditions
Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated specimens. 
Ambient: 24 hours; Refrigerated: 1 weeks; Frozen: 1 month 
Reference Interval
Test Number
Reference Interval
2012074SSA 52 and 60 (Ro) (ENA) Antibodies, IgG
Test Number
Reference Interval
SSA-52 (Ro52) (ENA) Antibody, IgG29 AU/mL or Less: Negative
30-40 AU/mL: Equivocal
41 AU/mL or greater: Positive
SSA-60 (Ro60) (ENA) Antibody, IgG29 AU/mL or Less: Negative
30-40 AU/mL: Equivocal
41 AU/mL or greater: Positive

0050599Scleroderma (Scl-70) (ENA) Antibody, IgG
29 AU/mL or lessNegative
30-40 AU/mLEquivocal
41 AU/mL or greaterPositive

0099592Jo-1 Antibody, IgG
29 AU/mL or lessNegative
30-40 AU/mLEquivocal
41 AU/mL or greaterPositive

2003040PM/Scl-100 Antibody, IgG by ImmunoblotNegative
0050465Rheumatoid Factor0-14 IU/mL
0055256Cyclic Citrullinated Peptide (CCP) Antibody, IgG
19 Units or lessNegative
20-39 UnitsWeak positive
40-59 UnitsModerate positive
60 Units or GreaterStrong positive

3000082Antinuclear Antibody (ANA) with HEp-2 Substrate, IgG by IFALess than 1:80
2001601RNA Polymerase III Antibody, IgG
19 Units or lessNegative
20-39 UnitsWeak Positive
40-80 UnitsModerate Positive
81 Units or greaterStrong Positive

 PL-7 (threonyl-tRNA synthetase) AntibodyNegative
 PL-12 (alanyl-tRNA synthetase) AntibodyNegative
 EJ (glycyl-tRNA synthetase) AntibodyNegative
 Ku AntibodyNegative
 SRP (Signal Recognition Particle) AbNegative
 OJ (isoleucyl-tRNA synthetase) AntibodyNegative
 NXP2 (Nuclear matrix protein-2) AbNegative
 MDA5 (CADM-140) AbNegative

Interpretive Data
Refer to report.

Compliance Statement D: For laboratory tests using a manufactured RUO kit. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Antibodies: Ro52, Ro60, Jo-1, PL-7, PL12, EJ, Ku, SRP, OJ, PM/Scl-100, MDA5, CCP, Scl-70, RA, ANA, NXP-2, RNA Polymerase III
Hotline History
View Hotline History
CPT Code(s)
83516 x9; 86235 x5; 86200; 86431; 86039
Component Test Code*Component Chart NameLOINC
0050465Rheumatoid Factor11572-5
0050599Scleroderma (Scl-70) (ENA) Antibody, IgG47322-3
0050691SSA-52 (Ro52) (ENA) Antibody, IgG31625-7
0055256Cyclic Citrullinated Peptide Ab, IgG33935-8
0099592Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG33571-1
2001602RNA Polymerase III Antibody, IgG79182-2
2003041PM/Scl 100 Antibody, IgG81732-0
2010853PL-7 (threonyl-tRNA synthetase) Antibody33772-5
2010854PL-12 (alanyl-tRNA synthetase) Antibody33771-7
2010856EJ (glycyl-tRNA synthetase) Antibody45149-2
2010857Ku Antibody18484-6
2010859SRP (Signal Recognition Particle) Ab33921-8
2010860OJ (isoleucyl-tRNA synthetase) Antibody45152-6
2012055SSA-60 (Ro60) (ENA) Antibody, IgG53019-6
2013998Interpretive Information48767-8
3000090Antinuclear Antibody (ANA), HEp-2, IgG21424-7
3000096ANA Interpretive Comment49311-4
3001787MDA5 (CADM-140) Ab82424-3
3001788NXP2 (Nuclear matrix protein-2) Ab82426-8
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.